From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – GYNAECO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in gynaeco
Prof Dr Christine Gennigens, a medical oncologist at the University Hospital of CHU de Liège, Belgium, summarised the “Stronger Together: Novel Combinations Across the Gynaecological Cancer Spectrum” session at ASCO
Prof Hannelore Denys, a medical oncologist at the University Hospital Ghent, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the Gynaecological Cancers session.
The BrUOG
In-depth stories about gynaeco
The ENGOT EN5 SIENDO study focuses on advanced or recurrent endometrial cancer. Initially, patients received a minimum of 12 weeks of TC (Taxol-Carbo) chemotherapy, followed by treatment with selinexor, an
Prof Toon Van Gorp discusses three highly interesting posters.
The first poster is about a study combining cemiplimab with an HPV16 vaccination (ISA101b) as a therapeutic vaccine for cervical cancer.
Prof Van Nieuwenhuysen discusses insights from the DUO-E trial, which included first-line endometrial cancer patients and those with first relapse. The trial enrolled 718 patients randomised into three groups: Taxol-Carbo
Gynaeco poster selection
The VENUS study is a prospective translational single-institution study that focuses on the molecular characterisation of cervical cancer histological subtypes. It involved 124 cervical cancer patients, primarily with stages 2
Ubamatamab is a bispecific antibody targeting MUC16 on ovarian cancer cells and CD3 on T cells, inducing a cytotoxic T cell response. Its efficacy is being explored in recurrent ovarian
This poster presents findings from the Spectrum study, a single-center retrospective analysis of endometrial cancer cases between 2003 and 2019, utilising available tissue samples. The study aimed to determine the
The ENGOT-cx12 inovaTV 301 trial, co-authored by Professor Vergote and by Prof Gennigens, is a Phase 3 randomised controlled trial evaluating tisotumab versus physician’s choice of chemotherapy in second or